<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552236</url>
  </required_header>
  <id_info>
    <org_study_id>Ultrasound Elastography in HCC</org_study_id>
    <nct_id>NCT04552236</nct_id>
  </id_info>
  <brief_title>Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment</brief_title>
  <official_title>Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early Hepatocellular Carcinoma Recurrence After Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to evaluate liver stiffness as a marker of severity and duration of the underlying&#xD;
      liver disease to predict for early HCC recurrence after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and contributes to&#xD;
      enormous cancer-related deaths annually . Hepatocellular carcinoma is a frequent complication&#xD;
      of liver disease. Early recurrence is mainly tumour or treatment-related .&#xD;
&#xD;
      Liver fibrosis stagging is essential to evaluate the expected prognosis against the&#xD;
      concomitant therapies. Liver biopsy remain the gold standard for diagnosing liver fibrosis,&#xD;
      however, it is limited due to the associated costs, invasiveness, and intra and inter&#xD;
      observer variability. Patient discomfort, refusal and risk of complications. Ultrasound&#xD;
      Elastography is a non-invasive imaging method liver fibrosis staging . Ultrasound&#xD;
      Elastography is an imaging technology sensitive to tissue stiffness that was developed in the&#xD;
      1990s. It has been further developed and refined in recent years to enable quantitative&#xD;
      assessment of tissue stiffness. Elastography methods take advantage of the changed elasticity&#xD;
      of soft tissues resulting from specific pathological or physiological processes .&#xD;
&#xD;
      Elastography is an application, which produces the force coupled with a measurement system&#xD;
      for the deformities caused by the force. There are several types of forces: 1. static&#xD;
      compression induced externally by manual compression or internally by organ motion (heart,&#xD;
      vessel, and breathing) 2. Dynamic compression induced with a continuous vibration at a given&#xD;
      frequency 3. Impulse compression (transient vibration) induced externally by a transient&#xD;
      mechanical impulse ( Fibroscan) or internally by an ultrasound impulse (ARFI, SWE), both&#xD;
      compression types producing shear waves. While contrast-enhanced imaging is the first-line&#xD;
      approach in the diagnosis of HCC, recent report show that the non-invasively measured&#xD;
      stiffness of hepatic nodule could help to distinguish between malignant and benign liver&#xD;
      lesions.&#xD;
&#xD;
      The treatment of HCC depends on the stage of liver disease and in many cases, curative&#xD;
      resection is not possible. Therefore local ablative therapies, such as transarterial&#xD;
      chemoembolization (TACE) and radiofrequency ablation (RFA), are considered viable therapeutic&#xD;
      options . However, HCC might behave very differently and could show more or less of a&#xD;
      response to local ablative treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predicting early HCC recurrence after treatment by Ultrasound elastography</measure>
    <time_frame>Baseline</time_frame>
    <description>TO enhance surveillance and detect HCC recurrence as early as possible for further management</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound ELastography</intervention_name>
    <description>A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.&#xD;
When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCC and liver cirrhosis expected to visit Assiut university hospital to be&#xD;
        treated&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with liver cirrhosis and HCC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic hepatic focal lesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Reem El shazly</last_name>
    <phone>+201014122696</phone>
    <email>saadreem89@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263. Review.</citation>
    <PMID>30970190</PMID>
  </reference>
  <reference>
    <citation>Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol. 2019 Mar;70(3):440-448. doi: 10.1016/j.jhep.2018.10.022. Epub 2018 Oct 31.</citation>
    <PMID>30389551</PMID>
  </reference>
  <reference>
    <citation>Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. Aliment Pharmacol Ther. 2016 Aug;44(4):366-79. doi: 10.1111/apt.13710. Epub 2016 Jun 30.</citation>
    <PMID>27363528</PMID>
  </reference>
  <reference>
    <citation>Gennisson JL, Deffieux T, Fink M, Tanter M. Ultrasound elastography: principles and techniques. Diagn Interv Imaging. 2013 May;94(5):487-95. doi: 10.1016/j.diii.2013.01.022. Epub 2013 Apr 22. Review.</citation>
    <PMID>23619292</PMID>
  </reference>
  <reference>
    <citation>Shiina T, Nightingale KR, Palmeri ML, Hall TJ, Bamber JC, Barr RG, Castera L, Choi BI, Chou YH, Cosgrove D, Dietrich CF, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. Ultrasound Med Biol. 2015 May;41(5):1126-47. doi: 10.1016/j.ultrasmedbio.2015.03.009. Epub 2015 Mar 21. Review.</citation>
    <PMID>25805059</PMID>
  </reference>
  <reference>
    <citation>Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008 Apr;48(4):606-13. doi: 10.1016/j.jhep.2007.11.020. Epub 2008 Jan 3.</citation>
    <PMID>18222014</PMID>
  </reference>
  <reference>
    <citation>Jiao Y, Dong F, Wang H, Zhang L, Xu J, Zheng J, Fan H, Gan H, Chen L, Li M. Shear wave elastography imaging for detecting malignant lesions of the liver: a systematic review and pooled meta-analysis. Med Ultrason. 2017 Jan 31;19(1):16-22. doi: 10.11152/mu-925. Review.</citation>
    <PMID>28180192</PMID>
  </reference>
  <reference>
    <citation>Conti CB, Cavalcoli F, Fraquelli M, Conte D, Massironi S. Ultrasound elastographic techniques in focal liver lesions. World J Gastroenterol. 2016 Mar 7;22(9):2647-56. doi: 10.3748/wjg.v22.i9.2647. Review.</citation>
    <PMID>26973405</PMID>
  </reference>
  <reference>
    <citation>Grgurevic I, Bokun T, Salkic NN, Brkljacic B, Vukelić-Markovic M, Stoos-Veic T, Aralica G, Rakic M, Filipec-Kanizaj T, Berzigotti A. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. Liver Int. 2018 Jun;38(6):1055-1063. doi: 10.1111/liv.13611. Epub 2017 Nov 3.</citation>
    <PMID>29028279</PMID>
  </reference>
  <reference>
    <citation>European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001. Erratum in: J Hepatol. 2012 Jun;56(6):1430.</citation>
    <PMID>22424438</PMID>
  </reference>
  <reference>
    <citation>Ho DWH, Chan LK, Chiu YT, Xu IMJ, Poon RTP, Cheung TT, Tang CN, Tang VWL, Lo ILO, Lam PWY, Yau DTW, Li MX, Wong CM, Ng IOL. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017 Aug;66(8):1496-1506. doi: 10.1136/gutjnl-2016-312734. Epub 2016 Dec 14.</citation>
    <PMID>27974549</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Reem Mohamed Saad EL Shazly</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://pubmed.ncbi.nlm.nih.gov/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

